US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Pacer WealthShield ETF

32.06

0.0000

Volume:9

Turnover:290.30

Market Cap:14.43M

PE:- -

High:32.06

Open:32.06

Low:32.06

Close:32.06

52wk High:33.83

52wk Low:31.18

Shares:450.00K

Float Shares:450.00K

Volume Ratio:0.00

T/O Rate:0.00%

Dividend:0.68

Dividend Rate:2.12%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Press Release: Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to Its Board of Directors

Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference

Press Release: Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Press Release: Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/PWS"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PWS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PWS\",,,,,undefined,":{"symbol":"PWS","market":"US","secType":"STK","nameCN":"Pacer WealthShield ETF","latestPrice":32.0568,"timestamp":1791558659465,"preClose":32.0568,"halted":0,"volume":9,"delay":0,"changeRate":0,"floatShares":450000,"shares":450000,"eps":0,"marketStatus":"Trading","change":0,"latestTime":"10-09 15:16:32 EDT","open":32.0568,"high":32.0568,"low":32.0568,"amount":290.301777,"amplitude":0,"askPrice":32.54,"askSize":1700,"bidPrice":32.48,"bidSize":1500,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1791576000000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"CBOE","adjPreClose":32.0568,"sharesOutstanding":950000,"nav":32.27,"aum":14521500,"dividendRate":0.021228,"bidAskSpread":0.002394,"postHourTrading":{"tag":"盘后","latestPrice":32.06,"preClose":32.0568,"latestTime":"16:10 EDT","volume":6,"amount":192.3408,"timestamp":1791490204420,"change":0.0032,"changeRate":0.0001,"amplitude":0},"volumeRatio":0.000233},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PWS\",,,,,undefined,":{"symbol":"PWS","floatShares":450000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.000233,"shares":450000,"dividePrice":0.6805,"high":32.0568,"amplitude":0,"preClose":32.0568,"low":32.0568,"week52Low":31.18,"pbRate":"--","week52High":33.83,"institutionHeld":0,"latestPrice":32.0568,"committee":-0.0625,"eps":0,"divideRate":0.021228,"volume":9,"delay":0,"ttmEps":0,"open":32.0568,"prevYearClose":32.3237,"prevWeekClose":32.1643,"prevMonthClose":32.2523,"prevQuarterClose":32.2523,"fiveDayClose":32.1643,"twentyDayClose":32.6888,"sixtyDayClose":32.3977},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PWS\",params:#limit:5,,,undefined,":[{"date":"2026-09-03","symbol":"PWS","amount":0.33672,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-03","defaultRemindTime":1788442200000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-08","payableDate":"2026-09-03","currency":"USD","dateTimestamp":1788408000000,"payDate":"2026-09-08"},{"date":"2026-06-04","symbol":"PWS","amount":0.0682,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-04","defaultRemindTime":1780579800000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-08","payableDate":"2026-06-04","currency":"USD","dateTimestamp":1780545600000,"payDate":"2026-06-08"},{"date":"2026-03-05","symbol":"PWS","amount":0.016362,"announcedDate":"2026-03-04","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-05","defaultRemindTime":1772721000000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-09","payableDate":"2026-03-05","currency":"USD","dateTimestamp":1772686800000,"payDate":"2026-03-09"},{"date":"2025-12-30","symbol":"PWS","amount":0.25921895,"announcedDate":"2025-12-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-30","defaultRemindTime":1767105000000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-05","payableDate":"2025-12-30","currency":"USD","dateTimestamp":1767070800000,"payDate":"2026-01-05"},{"date":"2025-09-04","symbol":"PWS","amount":0.0796608,"announcedDate":"2025-09-03","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-04","defaultRemindTime":1756992600000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-10","payableDate":"2025-09-04","currency":"USD","dateTimestamp":1756958400000,"payDate":"2025-09-10"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PWS\",market:\"US\",,,undefined,":[{"executeDate":"2018-03-27","recordDate":"2018-03-28","paymentDate":"2018-03-29","value":0.0522982,"currency":"USD"},{"executeDate":"2018-06-26","recordDate":"2018-06-27","paymentDate":"2018-06-28","value":0.0481106,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-09-27","value":0.1105742,"currency":"USD"},{"executeDate":"2018-12-24","recordDate":"2018-12-26","paymentDate":"2018-12-27","value":0.0682115,"currency":"USD"},{"executeDate":"2019-03-26","recordDate":"2019-03-27","paymentDate":"2019-03-28","value":0.1385698,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PWS\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PWS\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673741710","title":"Press Release: Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2673741710","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673741710?lang=en_us&edition=fundamental","pubTime":"2026-10-08 20:00","pubTimestamp":1791460800,"startTime":"0","endTime":"0","summary":"Brings more than 25 years of experience in clinical strategy, biostatistics and regulatory submissions from Abivax, Alumis, MyoKardia and Genentech/RocheSAN DIEGO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Aa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD","R","BK4007","BK4232","BK4022","PWS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672309780","title":"Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2672309780","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672309780?lang=en_us&edition=fundamental","pubTime":"2026-10-01 05:30","pubTimestamp":1790803800,"startTime":"0","endTime":"0","summary":"NEW YORK, Sept.  30, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a clinical stage biotechnology company focused on developing h","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/30/3372437/0/en/bright-minds-biosciences-to-participate-in-the-2026-fpwr-research-symposium-and-pws-family-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FPWR","BK4135","PWS","BK4139","DRUG","CNS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658451129","title":"Press Release: Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658451129","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658451129?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:53","pubTimestamp":1786481580,"startTime":"0","endTime":"0","summary":"and the OLE  trial to assess the totality of. available efficacy and safety data and to support an informed. determination of next steps for the ARD-101 program. In June 2026, the. Company terminated the HERO and the OLE trial and does not currently. intend to resume these trials as previously designed.-- In May 2026, the Company announced that the U.S. Food and Drug. Administration  placed a full clinical hold on its investigational. new drug application  for ARD-101, related to the Company's. previously announced voluntary pause. The clinical hold applies to all. previously ongoing clinical studies under the IND, including the Phase 3. HERO trial evaluating ARD-101 for the treatment of hyperphagia in. patients with Prader-Willi Syndrome  and the Phase 3 OLE trial.Second Quarter 2026 Financial Highlights-- Cash Position: As of June 30, 2026, Aardvark had cash, cash equivalents. and short-term investments of $73.9 million, compared to $91.2 million as. of March 31, 2026. Based on curre","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMED","IND","AARD","HYLG","IDNA","MEDX","NVIB","GDOC","PWS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657657184","title":"Press Release: Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2657657184","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657657184?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:05","pubTimestamp":1786046700,"startTime":"0","endTime":"0","summary":"-- Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP. manufacturing of clinical trial material underway. Initiation of the. Phase 3 RESCUE registrational program upon IND clearance.-- Sepranolone IND filing expected by year-end 2026 and initiation of Phase. 2 proof-of-concept study in Prader-Willi Syndrome upon IND clearance.-- Strengthened the leadership team with appointment of Bipin Dalmia as. -- Added to the Russell 2000 and Russell 3000 Indexes effective June. -- Cash balance of $217.7 million as of June 30, 2026, expected to fund. operations through 2029, including completion of the NDV-01 Phase 3","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKVL7J92.USD","BK4139","BK4567","IE00BHPRN162.USD","LU2413666426.HKD","IE00BZ1G4Q59.USD","IE00BFXG1179.USD","IE00BN0W2V16.EUR","BK4585","LU0170899867.USD","LU0882574139.USD","LU2229751404.USD","LU2413666699.HKD","RLMD","LU0971096721.USD","LU2237443622.USD","IE00BN0W2T93.GBP","LU2237443895.HKD","LU1721428933.USD","LU2237443465.HKD","PSIL","ALLO","IE00B1BXHZ80.USD","IE00BN0W2W23.USD","R","BK4539","LU1721429741.USD","LU2746668461.USD","BK4588","LU2092937221.SGD","LU1543694498.USD","LU2089279066.USD","BK4007","BK4232","LU1721429402.USD","LU0149725797.USD","LU0347712357.USD","CMC","BK4006","LU2237443978.SGD","IND","LU2746668974.SGD","LENZ","EES","LU2237443549.SGD","BK4505","LU2041044095.USD","BK4121","A","PWS"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":4,"pageCount":1,"totalSize":16,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/PWS\",params:#limit:6,delay:false,,,undefined,":[]}}